Sign Up to like & get
recommendations!
1
Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2160
Abstract: LncARSR (lncRNA Activated in RCC with Sunitinib Resistance, ENST00000424980) is a newly identified lncRNA to promote the sunitinib resistance of renal cell carcinoma (RCC), which may contribute to tumorigenesis and progression. This study aimed to…
read more here.
Keywords:
renal cell;
risk;
cell carcinoma;
resistance ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Cancers"
DOI: 10.3390/cancers14194762
Abstract: Simple Summary After initially responding to empiric radio-chemotherapy, most advanced thymomas and thymic carcinomas become refractory and require second-line therapies. The multi-target tyrosine kinase inhibitor, sunitinib, is one of few options, especially in patients with…
read more here.
Keywords:
mediator sunitinib;
thymic carcinomas;
sunitinib;
resistance ... See more keywords